glp 1 agonist dementia Could diabetes and weight loss drugs treat Alzheimer's disease? Mapping the effectiveness and risks

1 2 3 4 "GLP-1 drugs are transforming diabetes, obesity and more

Couzin-Frankel 22 Sept 2023 Barany, Barany)

DOI: 10.1097/01.NPR.0000000000000430,

Similar content being viewed by others 1 Introduction Semaglutide (US brand name Ozempic or Wegovy), a Glucagon-like peptide-1 receptor (GLP-1R) agonist containing the active ingredient semaglutide, is approved by the Food and Drug Administration for its potential therapeutic role in obesity and diabetes mellitus (DM) similar to other agonists within the GLP-1R family such as liraglutide

Retatrutide decreased HbA1c by 2.02% in a phase II clinical trial, while dulaglutide 1.5 mg decreased HbA1c by 1.14% and a placebo decreased it by 0.01% [109]